NVS

Novartis AG Form 6-K Summary: First Nine Months 2008

Business Context and Reporting Period

This Form 6-K, dated October 20, 2008, reports the financial results for Novartis AG for the nine months ended September 30, 2008, and the third quarter of 2008. The company is a global healthcare provider focused on pharmaceuticals, vaccines, diagnostics, generics (Sandoz), and consumer health. The reporting period reflects a strategic shift to continuing healthcare operations following the divestment of the Gerber and Medical Nutrition businesses in 2007.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 12% (4% in local currencies), driven by volume growth (+5 percentage points) and favorable currency translation (+8 percentage points). Pharmaceuticals sales grew 11% (4% lc), while Vaccines and Diagnostics grew 20% (15% lc).
• Profitability: Operating income rose 24% to $7.3 billion. Excluding a one-time $590 million environmental provision charge in Q3 2007, operating income growth was 13%. Operating margins expanded across all divisions, particularly Pharmaceuticals (30.2%) and Consumer Health (19.2%).
• Net Income Impact: Net income growth (19%) lagged operating income growth due to a higher effective tax rate in 2008 (14.0%) compared to an unusually low rate in 2007 (11.0%), and the inclusion of financing costs for the Alcon acquisition starting in July 2008.
• Liquidity and Debt: The company shifted from net liquidity of $7.4 billion at year-end 2007 to net debt of $2.7 billion as of September 30, 2008. This change was primarily due to the $10.4 billion cash payment for the 25% stake in Alcon and the acquisition of Speedel.

Guidance, Outlook, and Management Commentary

• Outlook: Management reaffirms expectations for record net sales and earnings for the full year 2008. Group net sales are expected to grow at a mid-single-digit rate in local currencies. Pharmaceuticals sales are projected to grow at a mid-single-digit rate, while Sandoz is expected to grow at a low-single-digit rate.
• Strategic Acquisitions: Novartis acquired a 25% stake in Alcon Inc. for $10.4 billion and Speedel Holding Ltd. for approximately $850 million. An option exists to acquire the remaining 52% of Alcon between 2010 and 2011 for up to $28 billion.
• Efficiency Initiatives: The "Forward" initiative has delivered $714 million in cost savings in 2008, exceeding the target of $670 million. A new US commercial model is planned for 2009, involving a reduction of approximately 550 full-time equivalent positions in the US sales force.
• Pipeline: Three submissions received accelerated US priority review status, including Afinitor for kidney cancer. Over 10 major US/EU regulatory submissions are planned for 2008.
• Risks: The filing notes ongoing legal proceedings regarding Zometa/Aredia (osteonecrosis of the jaw), Average Wholesale Price (AWP) litigation, and investigations into the promotion of Trileptal and TOBI. Management states these are unlikely to have a material adverse effect but litigation is inherently unpredictable.

Investor Verification Checklist

• Alcon Acquisition Impact: Verify the long-term integration costs and the financial implications of the optional second-step acquisition of Alcon.
• US Market Recovery: Confirm the sustainability of the US Pharmaceuticals sales recovery following the generic competition impacts on Lotrel, Trileptal, and the Zelnorm suspension in 2007.
• Debt Servicing: Assess the impact of the increased debt load ($2.7 billion net debt) on future interest expenses and credit ratings (currently AA- / Aa2).
• Regulatory Pipeline: Monitor the approval status of key pipeline assets, specifically Afinitor, Menveo, and QAB149, which are critical for future growth.
• Legal Contingencies: Review updates on the Zometa/Aredia litigation and AWP investigations for potential future provisions or settlements.